Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Adial Pharmaceuticals Inc (NQ: ADIL )

2.660 USD UNCHANGED
Streaming Delayed Price Updated: 10:32 AM EST, Nov 30, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 2.620 (2)
Ask (Size) 2.660 (1)
Prev. Close 2.660
Today's Range 2.660 - 2.660
52wk Range 1.600 - 5.080
Shares Outstanding 20,298,156
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Adial Pharmaceuticals to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Tuesday, October 5, 2021
From ACCESSWIRE
Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Peri
From GlobeNewswire News Releases

Performance

YTD
+53.76%
+53.76%
1 Month
-15.29%
-15.29%
3 Month
-35.59%
-35.59%
6 Month
+3.50%
+3.50%
1 Year
+14.16%
+14.16%

More News

Read More
Adial Pharmaceuticals Announces Research Collaboration Agreement with the University of Virginia to Advance Next Generation Adenosine Compounds for Wound Healing
From GlobeNewswire News Releases
Adial CEO William Stilley Invited to Participate in Maxim Group’s Virtual Panel Series Conference: “Disruptors in the Mental Health Space”
From GlobeNewswire News Releases
Sysorex Elects Nasdaq-Listed Company CEO William Stilley to Board of Directors
From GlobeNewswire News Releases
This NASDAQ has Life Saving Advances in Today's Most Critical Bio-Science Fields of Cancer and Immune Related Disease, Including COVID-19: Avalon GloboCare Corp. (NASDAQ: AVCO)
Tags Science & Research Banking, Finance & Investment Computers & Internet
From Viz Release
Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From GlobeNewswire News Releases
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
From GlobeNewswire News Releases
Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder
From GlobeNewswire News Releases
Adial Pharmaceuticals to Host Conference Call Today at 11AM Eastern to Provide Clinical Update and Discuss Positive Business Developments
From GlobeNewswire News Releases
Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Positive Business Developments
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.